ImmunoMet Therapeutics Presents Updated Clinical Data from Phase1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting
News Release ImmunoMet Therapeutics Presents Updated Clinical Data from Phase1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting January 24, 2025 – Houston, Texas
ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer
News Release ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer November 17, 2022 – Houston, Texas ImmunoMet
ImmunoMet Therapeutics Announces Closing of Series C Financing
News Release ImmunoMet Therapeutics Announces Closing of Series C Financing October 19, 2022 – Houston, Texas ImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular
Immunomet Therapeutic’s compound featured in the pre-publication from experts at Cambridge University entitled “Structural Basis of Mammalian Respiratory Complex I Inhibition by Medicinal Biguanides”
News Release Immunomet Therapeutic’s compound featured in the pre-publication from experts at Cambridge University entitled “Structural Basis of Mammalian Respiratory Complex I Inhibition by Medicinal
Immunomet Therapeutics Inc. announces publication of “First-in-human study of IM156, a novel biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors”.
News Release Immunomet Therapeutics Inc. announces publication of “First-in-human study of IM156, a novel biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors”.
ImmunoMet Therapeutics Closes $10M Series B-1 and Announces Plans to Conduct a Food Effect Study
News Release ImmunoMet Therapeutics Closes $10M Series B-1 and Announces Plans to Conduct a Food Effect Study December 31, 2021 – Houston, Texas ImmunoMet Therapeutics,